Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy older adults — VialBase Research
medium
- GHRH analog increased GH pulse amplitude in older adults
- Preserved pulsatile pattern of GH secretion
- Short-term effects on insulin sensitivity observed
Summary
Clinical study evaluating a GHRH analog (related to CJC-1295 class) in healthy older adults, assessing effects on endogenous GH pulsatility and metabolic parameters. The study provides insight into how GHRH-based therapies restore GH secretion in aging populations while maintaining physiological patterns.
Key Findings
- GHRH analog increased GH pulse amplitude without changing pulse frequency
- Preserved the natural pulsatile pattern of GH release
- Increased 24-hour integrated GH secretion
- Modest increases in IGF-1 levels
- Some changes in insulin sensitivity noted (potential concern)
- Results support GHRH-based therapy as more physiological than GH replacement
Methodology
Clinical study in 16 healthy older adults (60-80 years). Participants received GHRH analog or placebo for 4 weeks. GH measured via frequent blood sampling (deconvolution analysis) to characterize pulsatile secretion. Insulin sensitivity assessed via OGTT.
Limitations
- Very small sample (n=16)
- Short duration (4 weeks)
- No body composition outcomes measured
- Insulin sensitivity changes raise metabolic safety questions
- Specific GHRH analog not identical to CJC-1295 (related class)
Relevance to Content
Supports the “CJC-1295 for aging” narrative — restoring youthful GH pulsatility in older adults. The insulin sensitivity finding is important for balanced content that discusses both benefits and risks. Useful for content targeting the anti-aging/longevity audience interested in GH optimization.
See Also
- Parent compound: CJC-1295